Abstract
TNF-alpha release and action are central in the pathogenesis of the local and systemic inflammatory responses that occur after intestinal reperfusion. In this study we examined whether IL-1 participated in the cascade of events leading to TNF-alpha production and TNF-alpha-mediated injury following reperfusion of the ischemic superior mesenteric artery in rats. Blockade of the action of IL-1 by the use of anti-IL-1 antiserum or administration of IL-1R antagonist (IL-1ra), a natural antagonist of IL-1Rs, resulted in marked enhancement of reperfusion-associated tissue injury, TNF-alpha expression, and lethality. In contrast, there was marked decrease in IL-10 production. Facilitation of IL-1 action by administration of anti-IL-1ra, which antagonizes endogenous IL-1ra, or exogenous administration of rIL-1beta suppressed reperfusion-induced tissue pathology, TNF-alpha production, and lethality, but increased IL-10 production. Exogenous administration of IL-10 was effective in preventing the increase in tissue or plasma levels of TNF-alpha, the exacerbated tissue injury, and lethality. An opposite effect was observed after treatment with anti-IL-10, demonstrating a role for endogenous production of IL-10 in modulating exacerbated reperfusion-associated tissue pathology and lethality. Finally, pretreatment with anti-IL-10 reversed the protective effect of IL-1beta on reperfusion-associated lethality. Thus, IL-1 plays a major role in driving endogenous IL-10 production and protects against the TNF-alpha-dependent systemic and local acute inflammatory response following intestinal reperfusion injury.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / antagonists & inhibitors
-
Adjuvants, Immunologic / physiology
-
Adjuvants, Immunologic / therapeutic use
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / antagonists & inhibitors
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Inflammation / immunology
-
Inflammation / pathology
-
Inflammation / prevention & control
-
Injections, Intravenous
-
Injections, Subcutaneous
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1 / administration & dosage
-
Interleukin-1 / antagonists & inhibitors
-
Interleukin-1 / physiology*
-
Interleukin-1 / therapeutic use
-
Interleukin-10 / administration & dosage
-
Interleukin-10 / biosynthesis*
-
Interleukin-10 / physiology
-
Interleukin-10 / therapeutic use
-
Intestinal Mucosa / metabolism
-
Intestines / blood supply*
-
Intestines / immunology
-
Intestines / pathology*
-
Male
-
Mesenteric Artery, Superior / physiopathology
-
Rats
-
Rats, Wistar
-
Receptors, Interleukin-1 / administration & dosage
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / antagonists & inhibitors
-
Recombinant Proteins / therapeutic use
-
Reperfusion Injury / immunology*
-
Reperfusion Injury / pathology*
-
Reperfusion Injury / prevention & control
-
Sialoglycoproteins / administration & dosage
-
Sialoglycoproteins / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Adjuvants, Immunologic
-
Anti-Inflammatory Agents, Non-Steroidal
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Receptors, Interleukin-1
-
Recombinant Proteins
-
Sialoglycoproteins
-
Tumor Necrosis Factor-alpha
-
Interleukin-10